Genprex, Inc. (NASDAQ:GNPX – Get Free Report) shares traded down 3.9% on Wednesday . The company traded as low as $1.93 and last traded at $1.96. 35,531 shares changed hands during trading, a decline of 62% from the average session volume of 94,474 shares. The stock had previously closed at $2.04.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Genprex in a report on Wednesday, May 15th.
View Our Latest Research Report on Genprex
Genprex Trading Down 3.9 %
Genprex (NASDAQ:GNPX – Get Free Report) last announced its earnings results on Wednesday, May 15th. The company reported ($3.69) EPS for the quarter, missing the consensus estimate of ($2.54) by ($1.15). On average, analysts expect that Genprex, Inc. will post -5.7 EPS for the current year.
About Genprex
Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.
See Also
- Five stocks we like better than Genprex
- How to Invest in Tech StocksĀ and Top Tech Stocks to Consider
- Stock Impact: McDonald’s Price War with Starbucks, Wendy’s
- Roth IRA Calculator: Calculate Your Potential Returns
- General Mills Q4 Sales Miss Expectations, Triggering Stock Drop
- Best Stocks Under $10.00
- Enovix Stock Rises 35% in Short-Squeeze: This Rally Has Legs
Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.